Disease mechanisms and emerging therapies: Protein kinases and their inhibitors in myocardial disease

Mark E. Anderson, Linda S. Higgins, Howard Schulman

Research output: Contribution to journalReview articlepeer-review

Abstract

Most clinically validated drugs for treating patients with cardiovascular disease target G-protein-coupled receptors (GPCRs) in the cell membrane. GPCRs engage and activate multiple intracellular signaling cascades, which are regulated by serine/threonine protein kinases. These protein kinases are cytoplasmic, more abundant than GPCRs, and have rapidly emerged as drug targets in cardiovascular diseases. One exciting potential advantage to targeting serine/threonine protein kinases rather than GPCRs is the capability of influencing more precisely the diverse biological responses that are initiated by a common GPCR. On the other hand, highly specific targeting of individual protein kinases for drug therapy presents some medicinal chemistry challenges. This concise review focuses on the biology of serine/ threonine protein kinases in the cardiovascular system, discusses the current state of protein kinase inhibitor drug development for myocardial diseases, and illustrates some of the unique medicinal chemistry considerations in targeting protein kinases.

Original languageEnglish (US)
Pages (from-to)437-445
Number of pages9
JournalNature Clinical Practice Cardiovascular Medicine
Volume3
Issue number8
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Disease mechanisms and emerging therapies: Protein kinases and their inhibitors in myocardial disease'. Together they form a unique fingerprint.

Cite this